Avacta pauses trading to pursue equity fundraise
- Investing.com
Metrics to compare | AVCT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipAVCTPeersSector | |
|---|---|---|---|---|
P/E Ratio | −8.8x | −4.8x | −0.3x | |
PEG Ratio | −0.19 | −0.06 | 0.00 | |
Price/Book | 89.5x | 4.6x | 2.6x | |
Price / LTM Sales | 2,986.4x | 6.8x | 3.0x | |
Upside (Analyst Target) | 30.9% | 168.4% | 58.6% | |
Fair Value Upside | Unlock | −4.6% | 8.4% | Unlock |
Avacta Group Plc, together with its subsidiaries, engages in the development of cancer therapies in the United Kingdom, South Korea, and internationally. The company’s lead product candidate is AVA6000, a peptide drug conjugate form of doxorubicin, which is an approved cancer drug with known severe toxicities. It also develops AVA6103, a peptide drug conjugate technology designed to deliver exatecan, a potent topoisomerase I inhibitor directly to tumors while limiting the exposure of the released exatecan in normal tissues; and AVA7100 that drives localization to fibroblast activation protein expressing tumors. The company was incorporated in 2003 and is headquartered in London, the United Kingdom.